Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 978-987

  Mattoo, Abid R ^a   Fitzgerald, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABT 263; ABT 737; immunotoxin and Mcl 1; SCLC

Indexed keywords

CASPASE 3; CASPASE 7; IMMUNOTOXIN; LIPOCORTIN 5; NAVITOCLAX; PROTEIN MCL 1; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TISSUE CULTURE; TUMOR XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; BIPHENYL COMPOUNDS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TRANSFERRIN; SMALL CELL LUNG CARCINOMA; SULFONAMIDES;

EID: 84871359162     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27732     Document Type: Article

References (31)

1. Gajewski TF,. Cancer immunotherapy. Mol Oncol 2012; 6: 242-50.
2. Topalian SL, Weiner GJ, Pardoll DM,. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29: 4828-36.
3. Weiner LM, Surana R, Wang S,. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10: 317-27.
4. FitzGerald DJ, Wayne AS, Kreitman RJ, et al,. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011; 71: 6300-9.
5. Curran KJ, Pegram HJ, Brentjens RJ,. Chimeric antigen receptors for T cell immunotherapy: current understanding and future direction. J Gene Med 2012; 14: 405-15.
6. Weldon JE, Pastan I,. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011; 278: 4683-700.
7. Schindler J, Gajavelli S, Ravandi F, et al,. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011; 154: 471-6.
8. Olsnes S,. The history of ricin, abrin and related toxins. Toxicon 2004; 44: 361-70. (Pubitemid 39070638)
9. Keppler-Hafkemeyer A, Brinkmann U, Pastan I,. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry 1998; 37: 16934-42. (Pubitemid 28566770)
10. Frankel AE, Kreitman RJ, Sausville EA,. Targeted toxins. Clin Cancer Res 2000; 6: 326-34. (Pubitemid 30111447)
11. Kreitman RJ, Arons E, Stetler-Stevenson M, et al,. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma 2011; 52 (Suppl 2): 82-6.
12. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al,. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27: 2983-90.
13. Bogner C, Dechow T, Ringshausen I, et al,. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol 2010; 148: 99-109.
14. Andersson Y, Juell S, Fodstad O,. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer 2004; 112: 475-83. (Pubitemid 39390614)
15. Amundson SA, Myers TG, Scudiero D, et al,. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000; 60: 6101-10.
16. Lynch TJ, Jr, Lambert JM, Coral F, et al,. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997; 15: 723-34. (Pubitemid 27074242)
17. Shoemaker AR, Mitten MJ, Adickes J, et al,. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008; 14: 3268-77.
18. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al,. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-16.
19. Rudin CM, Hann CL, Garon EB, et al,. Phase 2 study of single agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18: 3163-9.
20. Tahir SK, Wass J, Joseph MK, et al,. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010; 9: 545-57.
21. Traini R, Ben-Josef G, Pastrana DV, et al,. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther 2010; 9: 2007-15.
22. Batra JK, Fitzgerald DJ, Chaudhary VK, et al,. Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol 1991; 11: 2200-5. (Pubitemid 21895592)
23. Hann CL, Daniel VC, Sugar EA, et al,. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321-8. (Pubitemid 351521806)
24. Tahir SK, Yang X, Anderson MG, et al,. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176-83.
25. Tse C, Shoemaker AR, Adickes J, et al,. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-8.
26. Oltersdorf T, Elmore SW, Shoemaker AR, et al,. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-81. (Pubitemid 40825512)
27. Meikrantz W, Schlegel R,. Apoptosis and the cell cycle. J Cell Biochem 1995; 58: 160-74.
28. Joe AK, Liu H, Suzui M, et al,. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002; 8: 893-903. (Pubitemid 34742123)
29. Zhang Y, Xiang L, Hassan R, et al,. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006; 12: 4695-701. (Pubitemid 44297823)
30. Zhang Y, Xiang L, Hassan R, et al,. Immunotoxin and taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 2007; 104: 17099-104. (Pubitemid 350210998)
31. Risberg K, Fodstad O, Andersson Y,. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One 2011; 6: e24012.